Anti-Covid Medicine: An expert panel of the Central Drugs Standards Control Organization (CDSCO) on Monday approved the manufacture and sale of anti-covid drug Malnupiravi for emergency use in the country for the treatment of Covid-19 patients. Official sources said.
The Serum Institute’s recommendation also approves Kovavax
Also, official sources said that the expert committee of the Drug Authority has recommended that the Covid-19 vaccine ‘Kovovax’ of the Serum Institute of India (SII) be allowed for emergency use under certain conditions. Prakash Kumar Singh, director of public and regulatory affairs at the Serum Institute of India (SII), submitted an application to the Drug Controller of India (DCGI) in October. Where commercial permission was requested for limited use of Kovavax in emergencies.
An expert committee on CDSCO’s COVID-19 (SEC) on Monday reviewed the Emergency Use Permit (EUA) application for a second time and, after detailed discussions, recommended approval for Kovovax’s emergency use. The expert committee discussed SII’s application with experts on November 27 and asked the pharmaceutical company to provide additional information on the matter.
This decision has been taken in the growing case of Omicron in the country
It is noteworthy that not only in the country, but also in the world, the incidence of new forms of Kovid Omicron is constantly increasing. The government has started imposing many restrictions in the wake of Omicron’s case. Many states, including Delhi, have imposed night curfews, while the government has also asked citizens to suspend New Year celebrations in the country.
Government warns of growing threat of Omicron, Night Curfew in 10 States, Restrictions in Delhi-Uttarakhand